The Lancet Neurology Publishes Data From Alkermes Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the...